A method for assaying poly (ADP-ribose) polymerase (PADPRP) activity in lymphocytes of systemic lupus erythematosus (SLE) patients has been developed. Using this method, PADPRP activity has been studied in lymphocytes from 15 patients and 13 controls. The mean activity in SLE lymphocytes was significantly lower than that in controls and 60% of the SLE patients demonstrated activities below the minimum of the control population. Possible mechanisms for this altered metabolism were investigated. The Km app of PADPRP for NAD; size distribution, branch frequency, and rates of turnover of polymers; competition for substrate; and number of PADPRP molecules were studied. The data demonstrated that SLE lymphocytes have a decreased synthetic capacity rather than alterations in the substrate or in turnover of the product.

Inhibition of enzymes in the isoprenoid biosynthetic pathway (IBP) plays an important role in the treatment of bone diseases and lowering cholesterol. The IBP begins with the enzyme HMG-CoA reductase catalyzing the conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid. Mevalonic acid is then converted to isopentenyl pyrophosphate (IPP) via the intermediate mevalonate-5-diphosphate. Three molecules of IPP are joined by the enzyme farnesyl diphosphate synthase (FDPS), which yields the intermediate farnesyl pyrophosphate (FPP). FPP is an important substrate and represents the branch point in the pathway. Compounds which disrupt this pathway at FDPS include risedronate, lovastatin, and zoledronate. It is believed these compounds express their pharmacological effects on a further downstream enzyme. Further downstream from FDPS the IBP includes the key enzymes geranylgeranyl diphosphate synthase (GGDPS), which is responsible for the production of geranylgeranyl pyrophosphate (GGPP) and necessary for protein prenylation of the proteins Ras, Rho, and Rab. The second key enzyme is geranylgeranyl transferase II (GGTase II), which is responsible for the transfer of GGPP to Rab proteins. Rab proteins, which play an essential role for both protein secretion and trafficking, are of great interest as a therapeutic target for the bone disease multiple myeloma. Multiple myeloma is a disorder of malignant plasma cells, characterized by the overproduction of monoclonal protein, antibodies, or light chains, which can ultimately thicken the blood. Targeting the prevention of geranylgeranylation of the Rab proteins by the enzyme GGTase II can happen through two different strategies. The first would be an indirect route, which would aim to inhibit the enzymes upstream from GGTase II. This could include the enzymes HMG-CoA reductase, FDPS, and GGDPS. Drugs that inhibit the earlier steps in the IBP indirectly prevent protein geranylgeranylation but they also limit formation of other key processes further downstream. The second approach would be a direct inhibition of the enzyme responsible for protein prenylation, GGTase II. There are very few know inhibitors of GGTase II. One such inhibitor is a carboxyphosphonate 3-PEHPC, a mimic of the bisphosphonate risedronate. Unfortunately, 3-PEHPC does not display an attractive potency. Efforts to develop a more potent inhibitor of the enzyme GGTase II, have focused on the preparation of a family of carboxyphosphonates containing a triazole core, and these compounds were prepared via click chemistry. Their activity has been studied, but the salts that were successfully made were ultimately inactive in comparison to 3-PEHPC. Previous attempts at forming isoprene-containing triazole carboxyphosphonates, as isoprene chains were shown to help increase activity towards GGTase II, proved difficult and unsuccessful. Focus was then switched to alteration of isoprene bisphosphonate triazoles as GGDPS inhibitors in attempts to increase activity towards this enzyme. The biological activity of these bisphosphonates was found to be selective and potent inhibitors of GGDPS, with little to no activity towards the GGTase II enzyme. In an effort to develop more potent inhibitors, isoprene triazole carboxyphosphonates were produced in an attempt to enhance the biological activity towards GGTase II. Along with forming a family of isoprene bisphosphonate compounds to increase the biological activity towards GGDPS in comparison to other previously made bisphosphonates. These carboxyphosphonate and bisphosphonate compounds were prepared through click chemistry and tested for their activity toward GGTase II and GGDPS.

The release of chemical transmitter from nerve terminals is critically dependent on a transient increase in intracellular Ca2+.6,25 The increase in Ca2+ may be due to influx of Ca2+ from the extracellular fluid15 or release of Ca2+ from intracellular stores such as mitochondria.1,8,18 Whether Ca2+ utilized in transmitter release is liberated from organelles other than mitochondria is uncertain. Smooth endoplasmic reticulum is known to release Ca2+, e.g., on activation by inositol trisphosphate or cyclic adenosine diphosphate-ribose,2 so the possibility exists that Ca2+ from this source may be involved in the events leading to exocytosis. We examined this hypothesis by testing whether inositol trisphosphate and cyclic adenosine diphosphate-ribose modified transmitter release. We used liposomes to deliver these agents into the cytoplasmic compartment and binomial analysis to determine their effects on the quantal components of transmitter release. Administration of inositol trisphosphate (10-4M) caused a rapid, 25% increase in the number of quanta released. This was due to an increase in the number of functional release sites, as the other quantal parameters were unaffected. The effect was reversed with 40min of wash. Virtually identical results were obtained with cyclic adenosine diphosphate-ribose (10-4M). Inositol trisphosphate caused a 10% increase in quantal size, whereas cyclic adenosine diphosphate-ribose had no effect. The results suggest that quantal transmitter release can be increased by Ca2+ released from smooth endoplasmic reticulum upon stimulation by inositol trisphosphate or cyclic adenosine diphosphate-ribose. This may involve priming of synaptic vesicles at the release sites or mobilization of vesicles to the active zone. Inositol trisphosphate may have an additional action to increase the content of transmitter within the vesicles. These findings raise the possibility of a role of endogenous inositol phosphate and smooth endoplasmic reticulum in the regulation of cytoplasmic Ca2+ and transmitter release.

No description available.

This work examines the synthesis of poly(ADP-ribose) in normal and SV40-transformed monolayer cultures of 3T3 cells as a function of growth and DNA fragmentation. A review of the relevant literature is given in the introduction of this work. Poly(ADP-ribose) synthesis has been implicated in transcription, replication, repair, differentiation and regulation of cell growth. The results of this study suggest that poly(ADP-ribose) synthesis is involved in some aspect of cell-growth control and DNA repair.

No description available.

Les isoenzymes de nucléoside diphosphate kinase (NDPK) sont connues depuis maintenant presque 60 ans et n'ont été considérées que pour leur activité catalytique de transfert de groupement phosphoryle. La découverte du gène nme, un gène antimétastatique codant une NDPK, a renouvelé l'intérêt scientifique pour cette famille d'enzymes. Il est désormais connu que la multiplication des gènes durant l'évolution a été accompagnée de diversifications structurales et fonctionnelles. J'ai étudié la fixation des NDPK-A, -B et –D (retrouvées associées aux membranes biologiques, bien que le rôle de cette association soit encore méconnu) à des membranes modèles, et j'ai trouvé des différences dans les mécanismes de fixation. J'ai montré la capacité de la NDPK-D, isoforme mitochondriale, à interagir avec des membranes anioniques ou zwitterioniques, à augmenter leur fluidité et à former des domaines protéolipidiques en présence de CL, lipide anionique spécifique de la membrane mitochondriale interne. J'ai observé cette capacité à former des domaines protéolipidiques avec d'autres protéines interagissant avec la CL, comme la créatine kinase mais pas le cytochrome C. La NDPK-A ne se fixe pas aux phospholipides du feuillet interne de la membrane plastique, ce qui suggère un autre partenaire in vivo. La NDPK-B n'interagit qu'avec des membranes anioniques via un processus en deux étapes, provoque une diminution de fluidité et est capable de former des domaines protéolipidiques. La ségrégation des lipides anioniques induite par la fixation de protéines pourrait contribuer à la formation de plateformes au sein de la membrane susceptibles de servir de point d'ancrage à de nombreuses molécules, modulant ainsi les fonctions cellulaires / Nucleoside diphosphate kinase isoenzymes (NDPK) have been known for nearly 60 years and, until recently, have been considered as housekeeping enzymes. The discovery of a nme gene, an antimetastatic gene that codes for a NDPK, revived the interest for this family. It is now known that the multiplication of nme genes throughout evolution has been accompanied with structural and functional diversification. I studied the binding of NDPK-A, -B and –D (which ae retrieved associated to cellular membranes where they are thought to play several roles) to model membranes and found differences in their behavior towards different compositions of phospholipids. I showed the ability of the NDPKD mitochondrial isoform to interact with both anionic and zwitterionic membranes, to modify their fluidity and to form proteolipidic domains in presence of CL, a mitochondrial inner membrane specific anionic lipid. I observed this ability to form proteo-cardiolipin domains with other CL interacting protein like creatine kinase but not with cytochrome c. NDPK-A was not able to bind to inner leaflet plasma membrane mimicking systems suggesting another partner in vivo. Concerning NDPK-B, it interacted only with anionic membranes via a two step-process, induced a decrease of the membrane fluidity and was able to form proteolipidic domains. Such anionic lipid segregation triggered by protein binding may contribute to platforms formation within membranes. Those platforms are then susceptible to provide a functional docking platform for numerous molecules and thus to modulate cellular functions

O presente trabalho teve como objetivo produzir comprimidos de liberação controlada de difosfato de primaquina baseados em polímeros hidrofílicos e otimizar a liberação do fármaco por meio do planejamento estatístico de mistura (DOE). Na seleção dos componentes da formulação foram realizados estudos de calorimetria exploratória diferencial (DSC) para verificar a compatibilidade entre o fármaco/excipientes e avaliação do fluxo dos pós das formulações por meio da determinação do ângulo de repouso. As 20 formulações obtidas no planejamento experimental continham misturas de hidroxipropilmetilcelulose de diferentes graus de viscosidade (K15M, K4M e K100LV) e polietilenoglicol 4000 como polímeros para controle da liberação. Os comprimidos de 30 mg de primaquina foram produzidos por compressão direta em máquina de punção simples de 9 mm e foram avaliados quanto à dureza, friabilidade, peso médio, teor do fármaco e dissolução. A cinética de liberação do fármaco foi estudada segundo os modelos de ordem zero, Higuchi e Korsmeyer-Peppas. Os ensaios de DSC permitiram verificar algum tipo de interação entre o fármaco e os excipientes lactose e estearato de magnésio. Os pós das formulações demonstraram boas propriedades de fluxo de acordo com os valores de ângulo de repouso. Os dados de regressão obtidos pelos modelos matemáticos aplicados com o DOE não permitiram verificar se a mistura de polímeros influenciou no ângulo de repouso dos pós e nas características físicas como dureza, friabilidade e peso médio dos comprimidos. No entanto, foi observada influência significativa da composição polimérica na dissolução dos comprimidos nos intervalos de 2, 4, 6 e 8 horas de ensaio. A partir desses dados e dos gráficos de superfície de resposta gerados pelo programa Design Expert® 6.0, foi possível otimizar as formulações restringindo a quantidade de cada polímero de forma a obter uma formulação com mecanismo de liberação duplo, por difusão e relaxamento das cadeias de polímero. O transporte anômalo foi o mecanismo de liberação de fármaco apresentado pela maioria das formulações, inclusive da formulação otimizada. / The objective of the present work was to produce primaquine diphosphate controlled release tablets based on hydrophilic polymers and use the mixture statistical experimental design (DOE) to optimize drug release. In selecting the components of the formulations, differential scanning calorimetry (DSC) were carried out to verify the compatibility between drug/excipients and evaluating flow properties of the powders by determining the angle of repose. The 20 formulations obtained in the experimental design contained mixtures of hydroxylpropylmethylcellulose of different degrees of viscosity (K15M, K4M and K100LV) and polyethylene glycol 4000 as polymers to control drug release. Tablets containing 30 mg of primaquine were produced by direct compression in a 9 mm single punch tablet press and were evaluated for hardness, friability, average weight, drug content and dissolution. The kinetics of drug release was studied applying Zero Order, Higuchi and Korsmeyer-Peppas models. DSC tests allowed verifying some kind of interaction between the drug and the excipients lactose and magnesium stearate. The values of angle of repose obtained demonstrated that the powders of the formulations presented good flow properties. The regression data obtained by the mathematical models failed to verify the influence of the mixture of polymers in the angle of repose of the powders and physical characteristics such as hardness, friability and average weight of the tablets. However, there was a significant influence of polymers composition in the dissolution of the tablets at intervals of 2, 4, 6 and 8 hours of testing. Most formulations showed anomalous transport as the mechanism of drug release. From these data and response surface plots generated by Design Expert® 6.0 software, it was possible to optimize the formulations by restricting the amount of each polymer to obtain a formulation with a double release mechanism, diffusion and relaxation of the hydrated matrix chains.

Thesis (Ph.D. in Pharmacology) -- University of Colorado Denver, 2007. / Typescript. Includes bibliographical references (leaves 132-151). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;

Thesis (Ph.D. in Neuroscience) -- University of Colorado at Denver and Health Sciences Center, 2006. / Typescript. Includes bibliographical references (leaves 108-118). Free to UCD Anschutz Medical Campus. Online version available via ProQuest Digital Dissertations;